16 / 63
Incorporating Bevacizumab and Erlotib in the combined-modality
treatment of stage III NSCLC: Results of a phase I/II trial
Trial
LCCC
9603
LCCC
2001
LCCC
0215
CALGB
30105
RTOG
0324
CALGB
30407
Socinski
2012
Nº p
62
29
23
43
87
101
45
Induction
QT
CbP CbP CbPI
CbP -
-
CbP
Beva
Concurrent
CbP CbP CbP+
gefitinib
CbP CbP +
Cetuxi
CbPem
+/-
Cetuxi
CbP
Beva
+
Erlotinib
TCRT, Gy
60-74 78-90 74
74
63
70
74
PFS rate 1
year, %
47
45
40
55
50
50
44
Median S,
m
26
24
16
24,3
22,7
21-25
18,4
Esophagiti
s,G 3 /4 %
8
16
19,5
16
8
13-16
29